‹ ›
MYP_016061
← PREVIOUS NEXT → BACK
Basic Information
EK1C4
Anticancer
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor cross
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
41 amino acids
C208H336N48O71S
Standard
Sequence
SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG
Physicochemical Analysis
4677.24 Da
4.36
-5.52
-5.76
-0.1347
-0.45
0.75
-0.02
21.17
104.63
0.0732
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1958.21
-15.67
66.0
67.0
168.0
328.0
3.0
42.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0274643 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG4-C16(palmitic acid)
PEG4-C16(palmitic acid)
Bio-Activity Profile
Antiviral Fusion inhibition
inhibition of authentic infection in Vero-E6-TMPRSS-2 cells
0.75 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperA Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern. | Lan Q, Chan JF, Xu W, Wang L, Jiao F, Zhang G, Pu J, Zhou J, Xia S, Lu L, Yuen KY, Jiang S, Wang Q. | Viruses. 2022 Mar 6;14(3):549. | DOI:10.3390/v14030549 | PMID:35336956 PMID35336956 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35336956/
RECORD: Rec_0278152 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG4-Chol
PEG4-Chol
Bio-Activity Profile
Antiviral Fusion inhibition
inhibition of cell-cell infusion in Caco2 cells
0.00088 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. | Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S. | Cell Res. 2022 Apr;32(4):404-406. | DOI:10.1038/s41422-022-00617-x | PMID:35087243 PMID35087243 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
RECORD: Rec_0278526 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG4-Chol
PEG4-Chol
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 Delta | of cell; -cell
0.00404 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. | Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S. | Cell Res. 2022 Apr;32(4):404-406. | DOI:10.1038/s41422-022-00617-x | PMID:35087243 PMID35087243 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
RECORD: Rec_0279334 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
PEG4-25-HC
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
(Beta):inhibition of Pseudoviruse infection in Caco2 cells
0.62 μM
IC50
PMID34769299 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34769299/
RECORD: Rec_0280567 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG4-Chol
PEG4-Chol
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 D614G
0.00558 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. | Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S. | Cell Res. 2022 Apr;32(4):404-406. | DOI:10.1038/s41422-022-00617-x | PMID:35087243 PMID35087243 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
FIRST PREV 1 ... 27 28 29 30 31 ... 39 NEXT LAST
Showing 5 records on this page · Page 29 of 39